With increasing use of protease inhibitors (PI) in Botswana, a large proportion of HIV-infected children are now exposed to PI-based regimens. There is limited protease genotype data from African children and adolescents who have failed PI-based antiretroviral therapy. We describe a cohort of pediatric HIV-infected patients experiencing virologic failure at time of second-line or salvage PI-based regimens and analyze associated PI mutations.
From the Botswana-Baylor Children’s Clinical Centre of Excellence, Gaborone, Botswana, and Baylor College of Medicine, Houston, TX.
Accepted for publication March 21, 2013.
The authors have no funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Andres Gomila, MD, Botswana-Baylor Children’s Clinical Centre of Excellence, Plot 1836, Hospital Way, Gaborone, Botswana. E-mail: firstname.lastname@example.org.